Cardiac arrest & resuscitation
Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): a randomized clinical trial
Authors' conclusion
Prehospital treatment with high-dose methylprednisolone to resuscitated comatose OHCA patients, resulted in reduced IL-6 levels after 24 h, but did not reduce NSE levels.
Study context
- Population
- Resuscitated comatose out-of-hospital cardiac arrest (OHCA) patients with suspected cardiac etiology, two cardiac arrest centers in Denmark
- Participants
- 137 patients
- Comparison
- Single IV injection of 250 mg methylprednisolone vs placebo
- Methylprednisolonen = 68
- Placebon = 69reference
- Primary endpoint
- Co-primary: reduction of IL-6 and neuron-specific enolase (NSE) blood levels measured daily
- Follow-up
- 72 h from admission
Methodological detailsblinded, placebo-controlled, phase II, prehospital, two centres
- Blinded
- Placebo-controlled
- Phase II
- Prehospital
- Two centres
Secondary outcomes
Survival (main secondary outcome) · 180 days
Original publication
Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): a randomized clinical trial. Intensive Care Med. Published 9 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →